Teva Pharmaceuticals is trading 4.42% down at ILA 12970.00, with no reliable report linking the decline to a new company-specific event. - On November 3, Teva’s earnings beat and raised outlook were reported as positive; its Tel Aviv shares rose 3.75% that session. - The provided broader-market indicators are modestly positive and do not clearly explain the November 4 decline. - A trial discontinuation was reported earlier, but available coverage does not establish it as the cause of the November 4 move.